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Abstract
Infectious challenge of the human nasal mucosa elicits immune responses that determine the fate of the host-bacterial
interaction; leading either to clearance, colonisation and/or disease. Persistent antigenic exposure from pneumococcal
colonisation can induce both humoral and cellular defences that are protective against carriage and disease. We challenged
healthy adults intra-nasally with live 23F or 6B Streptococcus pneumoniae in two sequential cohorts and collected nasal
wash, bronchoalveolar lavage (BAL) and blood before and 6 weeks after challenge. We hypothesised that both cohorts
would successfully become colonised but this did not occur except for one volunteer. The effect of bacterial challenge
without colonisation in healthy adults has not been previously assessed. We measured the antigen-specific humoral and
cellular immune responses in challenged but not colonised volunteers by ELISA and Flow Cytometry. Antigen-specific
responses were seen in each compartment both before and after bacterial challenge for both cohorts. Antigen-specific IgG
and IgA levels were significantly elevated in nasal wash 6 weeks after challenge compared to baseline. Immunoglobulin
responses to pneumococci were directed towards various protein targets but not capsular polysaccharide. 23F but not 6B
challenge elevated IgG anti-PspA in BAL. Serum immunoglobulins did not increase in response to challenge. In neither
challenge cohort was there any alteration in the frequencies of TNF, IL-17 or IFNc producing CD4 T cells before or after
challenge in BAL or blood. We show that simple, low dose mucosal exposure with pneumococci may immunise mucosal
surfaces by augmenting anti-protein immunoglobulin responses; but not capsular or cellular responses. We hypothesise
that mucosal exposure alone may not replicate the systemic immunising effect of experimental or natural carriage in
humans.
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Introduction
The human nasal mucosa forms the first line of defence against
challenge with inhaled bacteria, viruses and non-infectious
particles. The highly vascularised mucosa is an attractive niche
which permits a large and diverse community of bacterial species
to asymptomatically colonise the upper respiratory tract [1].
Invasion of the mucosa by colonising flora is prevented by innate
defence mechanisms supported by an interacting sub-mucosal
network of antigen presenting cells (macrophages and dendritic
cells) [2] with effector T and B lymphocytes [3,4]. The balance
between mucosal immune responses and the expression and
immunogenicity of bacterial virulence factors influence both
colonisation success and occurrence of invasive disease. Streptococcus
pneumoniae (pneumococcus) is a common nasal coloniser capable of
causing life threatening human disease worldwide [5]. Capsular
polysaccharide is a critical virulence factor but anti-capsular
antibodies alone do not account for the age related drop observed
in the rates of colonisation [6] or invasive disease [7]. An array of
additional virulence factors including pneumococcal surface
proteins A (PspA) and C (PspC) that mediate attachment to
epithelial cells and the pore forming toxin pneumolysin have been
shown to be critical for bacterial evasion of host defence [8]. These
pneumococcal proteins are immunogenic during colonisation
and/or disease [9] and are therefore of interest as vaccine
candidates. Mucosal vaccination with non-encapsulated whole
bacterial cells [10] or pneumococcal proteins [11,12] are attractive
strategies to elicit capsule independent immunity against pneu-
mococcal colonisation and/or disease.
Pneumococcal carriage is common in infants, particularly
among crowded, impoverished communities worldwide where
carriage rates range between 20 and 95% [5]. Infants serve as the
source of transmission to other children and adults [13] but
carriage rates decrease with increasing age as specific immunity
develops [14,15]. The pneumococcal specific immune responses
that develop during carriage and protect against subsequent
colonisation have been documented in mice and involve both
antigen specific T cells and specific antibody [14,16–19]. There
are reports in humans correlating T cell [20] and antibody [21,22]
responses to carriage. Pneumococcal carriage in infants [23,24]
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been associated with increases in the serum levels of immuno-
globulin against pneumococcal proteins and capsular polysaccha-
ride. Responses to pneumococcal proteins and to some extent
capsular polysaccharides [26] depend on support from antigen-
specific T cells to generate optimum levels of specific immuno-
globulin. Carriage is known to be an immunising event [25] but it
is likely that exposure without carriage also boosts levels of existing
immunity in healthy adults [27]. The end result is that in
European adults in contrast to infants, the rate of pneumococcal
carriage is very low despite frequent exposures.
We measured mucosal humoral and cellular immune responses
before and after intra-nasal live pneumococcal challenge in human
volunteers. We anticipated that pneumococcal intra-nasal chal-
lenge would lead to nasopharyngeal colonisation in our volunteers.
Our hypothesis was therefore that challenge would lead to
colonisation which would in turn elicit a humoral and cellular
mucosal response. Our hypothesis also included the converse
argument - that acute pneumococcal exposure (without colonisa-
tion) would not elicit a humoral and cellular mucosal response.
Systemic immunisation requires efficient targeting and retention of
antigen at inductive sites such as M cells or dendritic cells for
priming in naso-associated lymphoid tissue (NALT) [28] and we
did not know if this would occur or not following an acute
exposure to pneumococcus. Our results showed that we did not
achieve colonisation with 23F or 6B serotypes in 19 healthy adults.
The pneumococcal exposure alone increased mucosal but not
systemic pneumococcal specific immunoglobulin responses. Cel-
lular immunity in mucosal and systemic compartments was
unaltered by pneumococcal challenge.
Materials and Methods
Recruitment and ethics
Healthy adult volunteers were enrolled with written informed
consent to a study involving inoculation of either Streptococcus
pneumoniae type 23F or 6B, the two studies performed consecutively.
We recruited non-smoking adults aged between 18 and 60 years
with no history or signs of systemic or respiratory disease.
Individuals who were already naturally colonised with pneumococ-
cus or had regular contact with at risk individuals, such as young
children, were excluded from the study. Ethical approval was
obtained from the National Health Service Research Ethics
Committee, Sefton, Liverpool (08/H1001/52) and the study was
sponsored by the Royal Liverpool and Broadgreen University
Hospitals Trust.
Study design
Samples of blood, serum, nasal wash (NW) and bronchoalveolar
lavage (BAL) were obtained before and after bacterial challenge
according to two different sampling protocols (Figure 1). Volun-
teers in our first study were intra-nasally challenged with two doses
of 23F (Figure 1A) and in the second study a single dose of 6B
(Figure 1B) S. pneumoniae was used. In the 23F challenge cohort
NW samples were collected 2 weeks and 1 week before inoculation
and on days 2, 4, and 7 after each inoculation. In the 6B challenge
cohort (Figure 1B) NWs were collected 2 weeks before challenge
and 2 and 7 days following inoculation. NWs were then collected
once per week for 5 consecutive weeks. A final set of post-challenge
samples (blood, serum, NW and BAL) were then collected at 6
weeks.
23F and 6B preparation and volunteer inoculation
Clinical isolates of S. pneumoniae serotype 23F (P833 a gift of Prof.
JN Weiser, University of Pennsylvania) and 6B (BHN418 a gift of
Prof. P Hermans, University of Nijmegen) were used for
inoculation. Bacterial stocks were grown to mid-log phase in
Vegitone broth (Oxoid) [29] in order to avoid volunteer exposure
to animal products and stored in 1 ml aliquots of Vegitone with
10% glycerol (Sigma-Aldrich) at 280uC. Serotype confirmation
was performed using latex agglutination (Statens Serum Institute,
Copenhagen) and was confirmed by an independent reference
laboratory (Health Protection Agency, Colindale, UK).
On each day of inoculation two aliquots were thawed,
centrifuged and bacterial pellets were washed once before being
re-suspended and diluted in sterile 0.9% saline to reach the desired
concentration of bacteria. For the 23F cohort 9,000 CFU/naris in
100 ml saline were used for the first inoculation. If colonisation was
not established following this inoculation we performed a second
inoculation with 20,000 CFU/naris in 100 ml saline. For the 6B
cohort 40,000CFU/100 ml/naris was administered. Volunteers
tilted their head slightly back and 100 ml of bacterial suspension
was dropped onto each naris using a P200 pipette taking care not
to touch the mucosa. Serial dilutions of the original inocula were
plated onto blood agar for dose confirmation (Table 1).
Nasal washing and determination of carriage
NW samples were collected before and after challenge and
processed as previously described [30]. Briefly, a single aliquot of
5 ml normal saline was instilled into each naris with the subject
seated leaning back supported at 45u to the horizontal. At
instillation, the subject was invited to hold their breath and push
gently on the back of the upper teeth with their tongue. Saline was
held in the nasopharynx for 5 seconds and then poured out by
gently tipping the head forward while holding a Petri dish under
the nose. The samples collected from each naris were pooled. This
process was performed once for the 6B cohort but 3 times for the
23F cohort. Samples were transferred immediately to the
laboratory for processing. The first pooled aliquot obtained from
each NW visit in both cohorts was used to determine carriage
status (all negative except for one volunteer) and pneumococcal
Author Summary
Exposure to respiratory pathogens such as Streptococcus
pneumoniae (pneumococcus) is a frequent event that can
result in immediate clearance, nasal colonisation or disease
for the host. Human and mouse studies have shown that
natural colonisation is an immunising event. Colonisation
is prevalent in children but rare in human adults (,10%),
suggesting that despite high pneumococcal exposure
adult mucosal defences are sufficient to prevent colonisa-
tion. We exposed healthy adults to pneumococci in the
nose in order to achieve colonisation and mimic a natural
colonisation event. In most volunteers, however, we were
not able to obtain colonisation using this protocol. In
exposed but not colonised volunteers we measured
antibody and cellular responses in nose, lung and blood
samples. The mucosal defences elicited during acute
pneumococcal exposure are poorly described but these
data will shed light on the mechanisms that prevent
colonisation in healthy adults and inform future vaccine
design. Live bacterial exposure increases specific antibody
and innate responses at mucosal surfaces such as the nose
and lung. Systemic responses were not increased. These
data suggest that acute bacterial exposure per se
augments mucosal but not systemic defences. Natural or
experimental colonisation may be required for systemic
immunisation.
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3345 g for 10 minutes and the supernatant stored at 280uC. The
pellet was re-suspended in 100 ml of skim milk tryptone glucose
glycerol (STGG) preservative medium prior to plating. 25 ml was
plated onto Columbia Horse Blood Agar (Oxoid) with gentamicin
(Sigma) and the remainder diluted to 1 ml with STGG and plated
(50 ml) on blood and chocolate agar (Oxoid) for determination of
co-colonising flora. Remaining STGG samples were stored at
280u for long term storage [31] and confirmation if needed. Plates
were inspected after 24 hours incubation at 37uC, 5% CO2 and
alpha haemolytic, draughtsman-like colonies were sub-cultured to
determine pneumococcal phenotype. Optochin sensitivity, bile
solubility and latex agglutination testing were performed to
confirm pneumococcal phenotype. Subjects in whom pneumo-
cocci were not detected from NW samples collected on at least
2 consecutive visits were defined as non-colonised. Colonised
subjects are defined as subjects in whom pneumococci was
recovered from any nasal wash.
The numbers of lymphocytes in NW were too few for analysis of
cognate antigen specific T cell responses using flow cytometry. We
measured the NW total cell count and also examined stained
cytospin slides for increased numbers of cellular effectors and
mucus deposits. Total cell counts in NW were determined from
pooled aliquots 2 and 3 from the 23F cohort. Cells were pelleted at
400 g and resuspended in PBS. Cell counts were performed using
10 ml of cell suspension and a haemocytometer, with the final
count given per ml of NW fluid returned. The remainder was
pelleted as above and re-suspended in 50 ml of PBS and
centrifuged onto a microscope slide using a cytocentrifuge
(ThermoFisher Scientific) for 5 mins at 450 rpm. For the 6B
cohort a representative sample of 10 ml was taken from STGG
preparations (described above). These samples were made up to
50 ml with PBS and cytospins were prepared as described.
Microscope slides were allowed to air dry before staining with
Hemacolor rapid staining set (Merck, Germany) according to the
manufacturer’s instructions. An arbitrary semi-quantitative scoring
system was used to assign whether an increase, decrease or no
change had occurred.
Blood processing
Peripheral blood mononuclear cells (PBMCs) were isolated from
volunteer samples using Lymphoprep (Axis Shield, UK) according
to the manufacturer’s instructions. PBMCs were incubated at
37uC, 5% CO2 at a concentration of 5610
5 cells per ml/well in a
48-well plate in RPMI 1640 media with 2 mM L-glutamine (both
Sigma-Aldrich) and 10% human AB serum (Invitrogen, UK). Cells
were stimulated on the same day as collection.
Serum was obtained from clotted whole blood collected into
serum monovettes (Sarstedt, UK). Samples were centrifuged at
Figure 1. Experimental human intra-nasal 23F and 6B pneumococcal challenge study design. (A) 23F challenge and (B) 6B challenge. NW,
blood and BAL were obtained from each volunteer prior to (open symbols) and following (closed symbols) challenge with 23F (Arrows in upper panel
n=8) or 6B (Arrow in lower panel n=11).
doi:10.1371/journal.ppat.1002622.g001
Table 1. 23F and 6B cohort study details.
23F 6B
Total number of volunteers 8 11
Gender (M:F) 4:4 4:7
Age (mean6SD) 31616 2566
1
st challenge dose (per naris) (mean6SD) 8,79161,935 44,576612,815
2
nd challenge dose (per naris) (mean6SD) 13,83064,504 n/a
doi:10.1371/journal.ppat.1002622.t001
Pneumococcal Nasal Challenge Is Immunising
PLoS Pathogens | www.plospathogens.org 3 April 2012 | Volume 8 | Issue 4 | e10026222560 g for 7 minutes. Serum was taken and stored at 280uC for
immunoglobulin analysis.
BAL processing
Bronchoscopy was performed using topical local anaesthesia
with minimal sedation and BAL collected as described previously
[32]. Briefly, four aliquots, totalling 200 mls, of warm 0.9% saline
was instilled and gently retrieved from a sub-segmental bronchus
of the right middle lobe by gentle hand suction and the BAL
placed into sterile pots on ice. BAL was processed as previously
described [33]. Briefly, whole BAL was filtered through muslin to
remove mucus and 3 ml of unprocessed BAL was stored at
280uC. The whole sample was centrifuged at 470 g for
10 minutes. BAL supernatant was stored at 280uC for immuno-
globulin analysis. BAL cells were re-suspended in RPMI 1640
media as described for PBMCs with the addition of antibiotics
(penicillin 40 U/ml, streptomycin 40 mg/ml, neomycin 80 mg/ml
(all P4083, Sigma-Aldrich) and 0.5 mg/ml of amphotericin B
(A2942, Sigma-Aldrich). Total BAL macrophages and lympho-
cytes were counted and 5610
4 cells were centrifuged onto cytospin
slides for differential staining as described. Remaining cells were
then plated out into standard tissue culture plates to allow
macrophages to adhere for 3 hours at 37uC, 5% CO2. Non-
adherent cells were collected, washed and the pellet re-suspended
in media as described for PBMCs. These BAL cells were then
placed in 48-well plates at 37uC, 5% CO2 and stimulated on the
same day as collection as described below for PBMC and BAL
cells. For each volunteer we ensured that paired BAL cells
collected at each bronchoscopy were processed and incubated
using the same serum lot number and lymphocyte count/well
during stimulation.
Pneumococcal whole cell ELISA
Whole 23F (P833) and 6B (BHN418) strains were used as the
capture antigen to determine the antibody titer to the pneumo-
coccus in collected NW, BAL and serum. The whole cell ELISA
assay was performed as previously described [34]. Briefly, bacteria
stocks were grown in Todd Hewitt broth containing 0.5% yeast
extract (THY) to an optical density (OD600 nm) of 0.5. The
bacterial pellet collected after centrifugation was then re-
suspended in carbonate-bicarbonate buffer to an OD600 nm of 1.
This bacterial suspension was added to 96-well Maxisorp plates
(Nunc) (50 ml per well) and the plates were incubated overnight at
room temperature. After washing with PBS containing 0.05%
Tween 20 (PBS-T), wells were blocked with PBS containing 1%
bovine serum albumin (BSA). Eight-fold serial dilutions of samples
in 0.1% BSA were added and incubated for 2 hours at room
temperature in triplicate. Antigen-specific IgG and IgA antibodies
were detected using alkaline-phosphatase conjugated goat anti-
human IgG (Sigma) and biotin conjugated goat anti-human IgA
(AbD serotec, UK), respectively, followed by streptavidin-alkaline
phosphatase (AbD serotec, UK). 0.5 mg/ml of p-nitrophenyl
phosphate (PNPP) was added as a substrate. The OD was
measured at 405 nm using a FLUOstar Omega (BMG Labtech,
UK). The assigned titer value was determined as the last dilution
in which OD is above 0.1.
Measurement of anti-pneumococcal polysaccharide
antibodies by ELISA
Anti-pneumococcal capsular polysaccharide antibodies were
determined using the internationally standardised method and
reagents [35]. Briefly, 96-well ELISA plates were coated using
5 mg/ml of purified polysaccharides 6B or 23F (Statens Serum
Institute) for 5 hours at 37uC. Wells were blocked with 10% fetal
bovine serum in PBS (PBS-F) for 1 hour at 37uC. Plates were
washed 3 times with PBS-T between each step. Samples were
diluted in PBS-F containing 10 mg/ml cell wall polysaccharide
mixture (CWPS Multi, Statens Serum Institute) and incubated for
30 minutes at 37uC. When CWPS Multi is used, separate
adsorption with the 22F capsule, is not required. 89-SF5 reference
serum received from U.S. Food and Drug Administration was
used as a standard. Diluted/adsorbed samples were then
transferred to pre-coated plates and incubated overnight at 4uC.
Bound antibodies were detected using alkaline phosphatase
conjugated goat anti-human IgG (Sigma) for 2 hours at room
temperature. 0.5 mg/ml of p-nitrophenyl phosphate (PNPP) was
added as a substrate. Optical densities were measured at 405 nm
using a FLUOstar Omega microplate reader (BMG Labtech, UK).
All samples were run in triplicate in four dilutions. Results are
expressed as mg/ml calculated using the assigned IgG concentra-
tions in reference serum 89-SF5.
Measurement of anti-pneumococcal protein antibodies
The recombinant proteins PspA (clade1) [36] and PspC (group
5) [37] (GenBank accession numbers AY082387 and EF424119.1)
were kindly provided by Dr Eliane Miyaji (Butantan Institute,
Brazil). Pneumolysin toxoid (PdB) was provided by Prof. Aras
Kadioglu (University of Leicester, UK) and PsaA by Dr Eddie
Ades (CDC Atlanta, GA). Purified proteins were used to coat
ELISA plates at 1 mg/ml overnight. The assay was then performed
as described above for the pneumococcal whole cell ELISA. Anti-
PspA and anti-PspC concentrations were calculated using
reference serum samples with known concentrations assigned in
the laboratory of Prof. David Briles and Prof. Susan Hollingshead
for PspA, (both University of Alabama, USA) and Prof. Helena
Ka ¨yhty for PspC, (National Institute for Health and Welfare,
Helsinki, Finland). All samples were run in triplicate in four
dilutions. Anti-PdB and anti-PsaA concentrations are expressed in
arbitrary units per ml calculated using a standard serum sample.
Western blot analysis
We prepared whole cell extracts (WCE) and choline chloride
extracts (CCE) from the inoculated 23F pneumococcal strain
grown in THY to 0.6 OD600 nm. The cell pellet from 50 ml culture
was lysed in a solution containing 0.01% sodium dodecyl sulfate,
0.1% sodium desoxycholate, 0.15 M sodium citrate [38] or 2%
choline chloride [39], respectively. Choline chloride extraction is
more effective at releasing the choline binding proteins on the
pneumococcal surface. Protein extracts (5 mg of WCE and 3 mgo f
CCE) were separated in SDS-PAGE and transferred to a
nitrocellulose membrane. Individual lanes were incubated at
25uC for 6 h with matched pre- and post-challenge NW samples
(1:25 diluted) from inoculated volunteers. Protein-specific anti-
bodies were detected using goat anti-human IgG-HRP (Sigma-
Aldrich). Detection was performed using an enhanced chemilu-
minescence (ECL) kit (GE Healthcare). Comparisons were only
made between experiments in which the antibody incubation and
development of membranes were performed at the same time to
control for assay variation.
Preparation of pneumococci for cell stimulation
experiments
Serotype 23F and 6B S. pneumoniae were grown to mid-log phase
in Vegitone broth (Oxoid) at 37uC, 5% CO2. To obtain
pneumococcal culture supernatant, broth cultures were centri-
fuged and the supernatant was filtered first through 0.45 mm pore
Pneumococcal Nasal Challenge Is Immunising
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was then concentrated 10-fold by adding to pre-sterilised 10 K
molecular weight cut-off Vivaspin concentrators (VWR) and
centrifuging at 836 g for 25 mins at room temperature. This
processed cell supernatant from culture broth defined here as ‘23F
c/s’ or ‘6B c/s’ was stored at 220uC. Sterile Vegitone broth was
processed under the same conditions and used as a control for
stimulation experiments (‘vehicle’). Mid-log phase 6B pellet was
killed by heat treatment for 30 minutes at 56uC and kept at
220uC in single use aliquots in PBS. The protein content of 23F
c/s, 6B c/s, 6B pellet and vehicle was determined by Bradford
assay. In addition, ethanol-killed acapsulate derived type 2 S.
pneumoniae (gift of Prof. R Malley, Boston, USA) at a concentration
of 1610
6 cells/ml was used as an in vitro pneumococcal challenge,
relevant to the development of that product as a novel vaccine
[10].
PBMC and BAL cell stimulation
We collected PBMC and BAL samples from 19 volunteers
before and after challenge with 23F or 6B to determine whether
nasal challenge with pneumococcus was associated with alteration
in pneumococcal antigen-specific memory CD4 T cell responses in
either compartment. PBMC and BAL cells from volunteers
challenged with 23F were stimulated in vitro with the following
antigens: 23F c/s (0.395 mg/ml), vehicle (0.26 mg/ml), 10
6/ml
whole pneumococcal cells (acapsulate derived type 2 donated and
prepared [33] by Prof. Malley), 0.45 mg/ml heat-inactivated
influenza vaccine (Split Virion, Sanofi Pasteur 2009/2010 strains)
or left untreated (‘NS’). All experiments were performed in a
volume of 1 ml in 48-well plates. PBMC and BAL cells from
volunteers challenged with 6B were similarly stimulated in vitro
with the following antigens: heat killed 6B whole cells (1.0 mg/ml),
6B c/s (13 mg/ml of which 4.2 mg/ml was pneumococcal protein),
vehicle (13 mg/ml), 10
6/ml whole pneumococcal cells (acapsulate
derived type 2 donated by Prof. Malley), 0.45 mg/ml heat-
inactivated influenza (Split Virion, Sanofi Pasteur 2010/2011
strains) or left untreated (‘NS’). Staphylococcal enterotoxin B
(Sigma-Aldrich) was used at 0.5 mg/ml (final concentration) as a
positive control. Antigen titration experiments were performed to
determine the optimum concentration required for stimulation.
Cells were incubated for 2 hours at 37uC, 5% CO2. After 2 hours,
1 ml Brefeldin A (BD Biosciences, UK) was added and incubated
for a further 16 hours before harvesting and staining for the
presence of intracellular cytokines by flow cytometry.
Intracellular cytokine staining and flow cytometry
analysis
Cells challenged with antigen as above were spun to a pellet,
supernatant discarded and the cells stained for flow cytometry.
Cells were stained with Vivid according to the manufacturer’s
instructions (Invitrogen) to allow discrimination between viable
and non-viable cells. Cells were then stained for CD3, CD4 and
CD45RO using the following mouse anti-human monoclonal
antibodies, APC conjugated CD3, APC-H7 conjugated CD4, PE-
Cy7 conjugated CD45RO (all Becton Dickinson) on ice. Cells
were fixed and permeabilised (Cytofix/Perm) according to the
manufacturer’s instructions (BD Biosciences) then stained for
intracellular IFNc, TNF and IL-17 using mouse anti-human
antibodies: AF700 conjugated IFN-c,A F 488 conjugated TNF, PE
conjugated IL-17 (all BD Biosciences, UK). Cells were fixed prior
to acquisition on a BD LSR2 flow cytometer (Becton Dickinson,
UK). We gated viable, memory CD4 T cells (CD4+CD45RO+)
and performed a Boolean gating strategy (data not shown) to
identify the proportion of TNF, IFNc and IL-17 producing cells
(or combinations thereof) following in vitro stimulation with
Influenza (positive control), whole pneumococci or pneumococcal
culture supernatant from the respective challenge strain. In order
to correct for inter-subject variation in the response to the
Vegitone broth, all culture supernatant stimulated data were
corrected by subtracting the percentage of CD4+CD45RO+ cells
producing cytokine when cultured with Vegitone media alone
(‘‘vehicle’’) from the pneumococcal antigen stimulated response.
Responses to media alone were subtracted from Influenza or
whole cell stimulated cells to determine specific responses.
Statistical analysis
Immunoglobulin and flow cytometry data were tested to
determine the distribution of the data. Data with a normal
distribution (Shapiro Wilks) were compared with parametric tests
(paired students’ t-test for before vs after inoculation) and for data
not following a normal distribution; the Wilcoxon-matched pairs
test was used. Flow cytometry data were analysed using FlowJo
software version 7.6 (Treestar Oregon, USA). Graph and statistical
analysis was performed using GraphPad prism version 5.0
(California, USA). Differences were considered significant if
p#0.05.
Results
Recruitment and human pneumococcal challenge
Twenty volunteers were recruited and inoculated per protocol
as shown in Figure 1 with no adverse effects. One subject in the
23F cohort established experimental colonisation as a result of the
inoculation and is excluded from further description in this study.
In the first cohort 8 subjects received two doses of 23F mean dose
8,791 cfu/naris (SD61,935 cfu/naris) and 13,830 cfu/naris
(SD64,504 cfu/naris), given 2 weeks apart (Figure 1 A and
Table 1). In our second cohort we challenged 11 volunteers with a
single, mean dose of 44,576 6B cfu/naris (SD612,815 cfu/naris)
(Figure 1 B and Table 1). These remaining nineteen study
volunteers did not establish colonisation following pneumococcal
challenge, contrary to our initial expectations. We did not detect
pneumococci in any nasal washes obtained from these nineteen
volunteers. Details of the study participants who were challenged
with pneumococci are given in Table 1 for both 23F and 6B
cohorts.
Nasal wash volumes recovered were a mean of 5.9 ml (range 2.3
to 8.5 ml) for the 23F cohort and 6.5 ml for the 6B cohort (range 4
to 8.1 ml). BAL volumes with cell counts are shown in Table S1.
Intra-nasal pneumococcal challenge increases mucosal
pneumococcal specific IgG and IgA
Pneumococcal whole cell ELISA data were compared before
and after pneumococcal challenge in 3 compartments (NW, BAL
and serum) using samples from the first 7 volunteers for the 23F
cohort and 8 volunteers in the 6B cohort as shown in Figure 2.
Three volunteers were excluded from the 6B cohort as a full set of
paired samples were not obtained. In each cohort, the relevant
challenge pneumococcal strain was used as the ELISA target
antigen. Whole cell ELISA using 23F and 6B pneumococcus
detected antigen-specific IgG and IgA in all NW, BAL and serum
samples both before and after inoculating challenge. Antigen-
specific titers of pneumococcal specific IgG were much higher in
serum than in NW (200-fold) or BAL (1000-fold). Similarly, serum
levels of pneumococcal specific IgA were much higher than in NW
(10-fold for 6B and 100-fold for 23F) and BAL (100-fold for 6B
and 1000-fold for 23F). There was no association between volume
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samples.
Comparisons before and after nasal inoculation with bacteria
showed that there was no change in pneumococcus-specific IgG or
IgA in serum following inoculation with either 23F or 6B as shown
in Figures 2A and 2B. There was a significant increase in both IgG
(pre 25.467.5 vs post 52.567.5, p=0.05) and IgA titers (pre
47.5617.9 vs post 122657.6, p=0.03) in NW following 23F
inoculation, and a significant increase in IgA in NW following 6B
inoculation (pre 36614.4 vs post 58615.9, p=0.03) as shown in
Figures 2C and 2D. BAL data showed a significant increase in
anti-pneumococcal IgG titer following 23F (pre 662.5 vs post
16.268.6, p=0.03) but not 6B challenge (Figure 2E). Anti-
pneumococcal IgA responses in BAL before and after 23F or 6B
challenge were unaltered (Figure 2F). In summary, intranasal
inoculation of bacteria was associated with increased NW (IgG
and IgA) and BAL (IgG only) immunoglobulin responses but no
change in serum levels. These observations were dependent on
Figure 2. IgG and IgA responses to whole cell 23F or 6B pneumococci following 23F or 6B challenge, respectively. ELISAs were
performed using 23F or 6B pneumococci as targets to measure specific IgG (A, C and E) and IgA (B, D and F) titers in serum (A and B), NW (C and D)
and BAL (E and F). Values shown are the mean antibody titers (of triplicates), pre and post 23F (n=7)or6B(n=8) challenge (x-axis). *represents
statistical significance between pre- and post-inoculation antibody titers.
doi:10.1371/journal.ppat.1002622.g002
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IgA only) pneumococcal serotype.
Increased pneumococcal specific IgG and IgA responses
are directed towards pneumococcal proteins and not
capsular polysaccharide
We next determined which pneumococcal antigenic targets
were responsible for the increased antibody responses. We
measured anti-23F or 6B capsular polysaccharide responses before
and after challenge with the respective challenge strain in NW,
BAL and serum. There were no significant differences in 23F or
6B anti-capsular polysaccharide responses before and after
challenge in either cohort (Figure S1 A–C).
We followed up our observations in Figure 2, showing a
significant difference in IgG titer before and after 23F but not 6B
challenge, by performing Western blots to compare IgG responses
to 23F pneumococcal proteins on the same NW sample set.
Figure 3 shows results from NW taken from 8 subjects before
(Figure 3 Pre) and after (Figure 3 Post) nasal challenge with 23F.
There was more antigenic protein in each gel following CCE
compared to WCE. The dominant protein antigen seen in all NW
samples before challenge was a CCE band migrating to 110–
150 kDa. Following challenge with 23F (Figure 3 Post) there was a
general increase in the overall level of NW antibody binding in
both WCE and CCE lanes in all NW samples. There was
particularly increased reactivity towards the 110–150 kDa band in
all but one subjects and a new band slightly above 60 kDa in 5/8
donors (Figure 3 Post). These data indicate an increase in IgG
response towards pneumococcal proteins following 23F exposure.
Pneumococcal protein specific IgG is increased in NW
following 6B but not 23F challenge
We next used purified proteins in an ELISA to quantitatively
determine the specific pneumococcal proteins which elicited
increased total pneumococcal specific IgG responses in NW
following bacterial challenge. We measured anti-PspA, PspC, PdB
and PsaA IgG (Figure 4) levels in both 23F and 6B pneumococcal
challenge cohorts before and after challenge. In the 23F challenge
cohort we did not detect any difference in the concentration of
anti-PspA (Figure 4A), PspC (Figure 4B), PdB (Figure 4C) or PsaA
(Figure 4D) IgG before and after challenge. In the 6B challenge
cohort, we detected a significant rise in the mean concentration of
anti-PspA (pre 49.2612.7 vs post 301.56196.5, p=0.05)
(Figure 4A). The mean concentration of anti-PspC (pre
28.267.3 vs post 93.8655.5, p=0.07) (Figure 4B), anti-PdB (pre
2.360.8 vs post 21.4615.12, p=0.06) (Figure 4C) and anti-PsaA
(Figure 4D) (pre 2.861.2 vs post 22.5616.6, p=0.1) antibody
were all higher post 6B challenge compared to pre-challenge
samples but these differences were not statistically significant. The
Western blot and these ELISA data suggest that the antibody
response to whole pneumococci extends beyond these 4 studied
antigenic proteins.
Intra-nasal 23F pneumococcal challenge increases anti-
PspA IgG in BAL
Bacterial challenge with type 23F pneumococcus was associated
with increased BAL IgG titer in pneumococcal whole cell ELISA
but not with increased anti-capsular BAL IgG. We therefore
measured anti-pneumococcal protein IgG levels in BAL samples
Figure 3. Nasal wash IgG binding to pneumococcal proteins before and after 23F pneumococcal challenge by Western blot. Pre- and
post- 23F challenge NW samples from 8 volunteers were used to detect pneumococcal proteins present in whole cell (WCE) and choline chloride
extracts (CCE) of the challenge strain.
doi:10.1371/journal.ppat.1002622.g003
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PsaA IgG responses in BAL (Figure 5) for both challenge cohorts.
There was a significant increase in the concentration of anti-PspA
specific IgG in BAL following challenge with 23F (pre 96.4632.2
vs post 161.7657, p=0.03) but not 6B (Figure 5A). A higher
concentration of anti-PspC IgG in BAL following challenge with
23F (pre 37.9610.7 vs post 90.2632.3, p=0.07) was observed
(Figure 5B) but was not statistically significant. There were no
differences in the concentration of anti-PdB (Figure 5C) and PsaA
(Figure 5D) IgG in BAL before and after challenge with 23F.
There were no differences in protein specific responses in BAL
before and after 6B challenge (Figure 5A–D).
Pneumococcal 23F challenge decreases serum anti-PspA
Although there were no changes in serum observed following
bacterial challenge using either whole cell ELISA or capsular
polysaccharide ELISA, we measured anti-PspA, PspC, PdB and
PsaA IgG in serum before and after challenge with 23F or 6B
(Figure 6). In contrast to the increased anti-PspA measured in BAL
following 23F challenge there was a significant decrease in the
concentration of serum anti-PspA following challenge with 23F
(serum pre 125.6642 vs serum post 76.9614, p=0.03) but not 6B
(Figure 6A). The concentration of anti-PspC (Figure 6B), PdB
(Figure 6C) and PsaA (Figure 6D) were similar before and after
challenge for both 23F and 6B cohorts.
Pneumococcal challenge shows evidence of mild
inflammation
We next compared the cellularity and cellular responses in NW
samples obtained from subjects before and after pneumococcal
challenge from both 23F (first dose only) and 6B cohorts.
NW sample cellularity was low and variable (range 0–9300 total
cells) in samples collected. There was no difference in total cell
yield before and after challenge for the 23F cohort (Figure S2).
Increased levels of cellular effectors (neutrophils and mononuclear
cells) and/or granular mucus deposits (evidence of inflammation)
compared to baseline were seen on cytospins of NW preparations
in 4/8 volunteers 2 days after 23F challenge and in 2/8 volunteers
at 4 days. IL-17 ELISA (eBioscience, UK, Catalogue 88-7176-22)
performed according to the manufacturer’s instructions on NW
samples from 4 volunteers showed no detectable cytokine before
and after 23F challenge. In the 6B cohort 5/7 samples showed
Figure 4. Nasal wash IgG response to pneumococcal purified protein antigens. ELISAs were performed using pneumococcal antigens PspA
(A), PspC (B), PdB (C) and PsaA (D) to determine specific IgG in subject’s pre and post 23F (n=7)or6B(n=8) pneumococcal challenge (x-axis). Values
shown are the mean antibody concentration (of triplicates). Antibodies to PspA and PspC are expressed in mg/ml and antibodies to PdB and PsaA are
expressed in arbitrary units/ml (y-axis). *represents statistical significance between pre- and post-challenge antibody levels.
doi:10.1371/journal.ppat.1002622.g004
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samples taken immediately after 6B challenge compared with
before challenge.
Pneumococcal challenge is associated with altered
mucosal T cell memory in BAL but no increase in antigen-
specific T cell responses before and after challenge
There were no differences in BAL volume and total cell yield
before and after 23F or 6B challenge (Table S1). In the cohort
challenged with 23F, there was a significantly higher total
lymphocyte count (mean6SD Pre 1.960.75610
6 vs post
3.261.2610
6 p=0.006) after challenge compared to before in
BAL. The percentage of total T cells that were of the memory
CD4 phenotype was also significantly higher after challenge
compared to before (mean%6SD, Pre 40.05620.6 vs post
48.47614.7, p=0.048). Total BAL lymphocyte counts showed
correlation with the BAL anti-23F whole cell antibody titre
(p=0.01, Pearson correlation) and anti-PspA concentration
(p=0.03, Pearson correlation) for the 23F but not the 6B cohort
(Figure S3). In the cohort challenged with 6B, there was no
increase in total lymphocyte count, no increase in % memory CD4
T cells and no association of lymphocyte numbers with anti-
pneumococcal IgG by whole cell ELISA (Figure S3).
The data for antigen-specific T cell responses (baseline corrected)
are shown in Figure 7 as the percentage of memory CD4 T cells
producingat leastone cytokine(ofIFN-c, TNFor IL-17) beforeand
after the subject was intra-nasally inoculated with pneumococci.
Antigen-specific responses, to influenza and pneumococcal
preparations, compared to non-stimulated cells, were seen to a
varying degree in blood and BAL from both cohorts before
challenge. In the 23F cohort, significant antigen-specific responses
(compared with non-stimulated control) were seen to influenza in
BAL (mean%6SD, 0.8560.66 vs non-stimulated 0.4260.36
p=0.03, n=7) and blood (0.1560.05 vs control 0.0560.07,
p=0.03, n=8). There were no significant responses to pneumo-
coccal antigens before inoculation in blood or BAL but there were
significant responses to 23 c/s after inoculation in BAL (0.5560.28
vs vehicle 0.3560.16, p=0.032, n=8).
Figure 5. Bronchoalveolar lavage IgG response to pneumococcal antigens. ELISAs were performed using pneumococcal antigens PspA (A),
PspC (B), PdB (C) and PsaA (D) to determine specific IgG in subjects pre and post 23F (n=7)or6B(n=8) pneumococcal challenge (x-axis). Values
shown are the mean antibody concentration (of triplicates). Antibodies to PspA and PspC are expressed in mg/ml and antibodies to PdB and PsaA are
expressed in arbitrary units/ml (y-axis). *represents statistical significance between pre- and post-challenge antibody levels.
doi:10.1371/journal.ppat.1002622.g005
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pared to non-stimulated control) were seen to influenza in BAL
(0.560.29 vs non-stimulated 0.1960.09, p=0.02) but not blood.
We also detected significant responses to 6B whole pneumococci
but not 6B culture supernatant in BAL (0.4060.26 vs control
0.1860.09 p=0.05) before pneumococcal challenge. In blood we
detected significant responses to 6B c/s (0.6260.26 vs vehicle
0.2460.09, p=0.0020) but not 6B whole pneumococci before
challenge.
Paired comparisons, before and after challenge, did not show
any significant differences in the proportion of pneumococcal
specific cytokine producing memory CD4 T cells before and after
challenge with 23F (Figure 7A blood and 7B BAL) or 6B
(Figure 7C blood and 7D BAL) in blood or BAL.
Discussion
We anticipated that a low dose of live pneumococci delivered
intra-nasally would lead to colonisation and thus augmented
mucosal and systemic responses to pneumococci. Colonisation was
not achieved in this study but we have shown that human
inoculation with a low dose of live pneumococci elicits specific
mucosal responses in the absence of carriage. Healthy adult
volunteers with detectable humoral and cellular immunity to
pneumococci prior to inoculation showed increased immunoglob-
ulin responses in NW and BAL but not blood 6 weeks after
experimental bacterial inoculation. In particular, concentrations of
IgG measured following inoculation with 23F were increased
compared to baseline observations in NW and BAL but not in
serum using a whole bacteria ELISA. Concentrations of IgA
measured following inoculation with 23F or 6B were increased
compared to baseline observations in NW but not in BAL or
serum. These responses did not include IgG or IgA to
pneumococcal capsule. We measured IgG responses in NW,
BAL and serum towards four pneumococcal proteins. We found
that IgG anti-PspA was significantly elevated in NW (following 6B
challenge) and BAL (following 23F challenge) and accounted in
part to the elevated responses seen towards whole pneumococci.
Inoculation was associated with an increase in the absolute count
and percentage of mucosal memory CD4 T cells for the 23F
cohort but not with an increase in paired antigen-specific cellular
responses in either group.
Figure 6. Serum IgG response to pneumococcal antigens. ELISAs were performed using pneumococcal antigens PspA (A), PspC (B), PdB (C)
and PsaA (D) to determine specific IgG in subjects pre and post 23F (n=7)or6B(n=8) pneumococcal challenge (x-axis). Values shown are the mean
antibody concentration (of triplicates). Antibodies to PspA and PspC are expressed in mg/ml and antibodies to PdB and PsaA are expressed in arbitrary
units/ml (y-axis). *represents statistical significance between pre- and post-challenge antibody levels.
doi:10.1371/journal.ppat.1002622.g006
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frequently in infancy [5] and less commonly in adult life [40]. The
most dramatic reduction in carriage and also disease rate occurs in
the second year of life [41] independent of capsular serotype [7].
Humoral and cellular responses to pneumococcal capsular
polysaccharide and protein antigens develop during this time.
These immunological developments contribute towards a much
lower incidence of pneumococcal mucosal and invasive disease in
older children and young adults than in infants [41,42]. Repeated
episodes of carriage and possibly pneumococcal exposure [13] are
thought to boost these important defences.
Experimental human pneumococcal carriage (EHPC) in adults
offers the platform to measure these responses [43]. EHPC in
immune adults has been previously reported [25,44] but there has
been no previous quantitative report of the mucosal humoral and
cellular immune response to challenge not resulting in carriage.
Most adult exposures to pneumococcus do not result in carriage
and indeed in our experimental pneumococcal inoculations, only
one healthy adult progressed to carriage. This result is surprising
given that the inoculated dose per naris for both cohorts in our
study (Table 1) is similar (23F) or higher (6B) than the CFU dose
described by McCool and Weiser [25] for their colonised
(12,00065,477/naris) and uncolonised (7,25064,062/naris)
groups. Colonisation success rate will depend on challenge dose
but also on the sensitivity of detection, exposure to other non-/
infectious agents, presence of co-morbidities, genetic factors,
opacity (i.e. capsule expression) of the challenge strain [45] and
study design.
The usefulness of the EHPC model depends on the sensitivity of
assays for detection of carriage. Sample collection by nasal swab
followed by enrichment for pneumococci using STGG medium
and subsequent bacterial culture is the current gold standard
method [46]. A previous EHPC model used throat and nasal swab
or wash with standard bacteriological culture media [25]. We
demonstrated that a NW sample is not only more comfortable for
the volunteer but better than swabs for detecting upper respiratory
flora [30] including pneumococcus [47]. We employed a method
combining NW collection and direct plating followed by storage
in STGG broth at 280uC [30]. A molecular approach to
pneumococcal identification may yield greater sensitivity com-
pared to culture [48,49], but it does not distinguish between
carriage, which implies the presence of viable pneumococci, and
retention of bacterial antigen from non-viable cells. A sophisticated
molecular approach [48] will resolve these issues in the future but
Figure 7. Frequency of antigen specific CD4 T cell responses before and after 23F or 6B challenge. Blood (A and C) and BAL (B and D)
responses are shown pre and post 23F (A and B) or 6B (C and D) challenge. The proportion of flu and pneumococcal specific (x-axis) CD4+CD45RO+ T
cells producing either TNF 6 IFNc 6 IL-17 (or combinations thereof) (y-axis) were analysed by multi-parameter flow cytometry. Shown are mean
values 6 SD of at least 6 paired samples.
doi:10.1371/journal.ppat.1002622.g007
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colonised below the detection limit of the current gold standard
method. The major strength of this study, however, is that it
focused on the immunological impact of a potentially infecting
dose of pneumococcus [25] on healthy adults with proven previous
natural pneumococcal exposure. We have been able to describe
responses in the inoculated site (nasopharynx), distal airway and
circulating blood.
The onset of carriage and acquisition of immunity in infants has
been successfully modelled using mice. These models have shown
that intra-nasal inoculation using live [14,16,17,50] or ethanol
killed [10] pneumococci or recombinant proteins [37,51–54]
(some with adjuvant) can elicit humoral and cellular immune
responses that protect against subsequent colonisation [14,16–18]
and/or disease [16,17]. Murine models can dissect the relative
contribution of humoral and cellular defence [55] but are a better
model of infancy (naive response) than of adults with pre-existing
memory responses. We have shown for the first time that levels of
anti-protein IgG and IgA against pneumococus were boosted in
both NW and BAL following intranasal challenge with pneumo-
cocci, though this depends on the serotype used. The implication
of this finding is that exposure to low doses of pneumococcus is
potentially immunising at the mucosal surface. A limitation of this
study, however, is that the samples collected from the nasopharynx
and lung are so dilute that functional measurement of the
opsonophagocytic effect of the observed increase in immunoglob-
ulin concentration is not currently possible. Previous studies in
several laboratories including ours [56] have attempted to
concentrate BAL in order to measure opsonic function. Concen-
tration in this way allows binding to be determined but enhanced
phagocytosis following immunisation has not been demonstrated.
It is interesting that there was no significant change in IgG or
IgA to polysaccharide capsule following inoculation. This
somewhat counter-intuitive observation is consistent with previous
data showing a lack of BAL response to inhaled polysaccharide
[57]. Human experimental colonisation however enhanced serum
polysaccharide responses in 5/6 volunteers [25] suggesting
colonisation has a greater systemic immunising effect compared
to challenge. Polysaccharide responses are initiated in the spleen
and plasma cells are found in very low numbers in BAL. In the
current study we know that bacterial clearance from the
nasopharynx was achieved in less than 2 days (probably more
rapidly) and it is therefore reasonable to suggest that polysaccha-
ride and bacterial protein were not presented to critical sites or
cells to enhance systemic immunity. IgG to polysaccharide capsule
is a critical defence mechanism against invasive pneumococcal
disease but is less important in defence against carriage [18]. Our
data suggest that experimental pneumococcal exposure without
carriage does not augment this limb of systemic defence.
We showed altered mucosal responses to protein antigens,
particularly choline bound proteins such as PspA. Using Western
blot and whole cell ELISA, more IgG to pneumococcal protein
was found after inoculation than before in both NW and BAL in
the 23F cohort. The Western blots show a greater effect of
inoculation on the choline binding proteins than on proteins
extracted without choline chloride. Specific anti-protein ELISA
was only able to detect a statistically significant difference in one of
the 4 proteins tested (PspA) although NW IgG levels to the other
three were all increased in the 6B challenged cohort. There are
many pneumococcal surface-proteins that function as virulence
factors and are sufficiently surface exposed to have vaccine
potential. Some of these pneumococcal surface proteins, including
PspA, PspC and PsaA, have been shown to have roles in adhesion
and carriage and may vary in expression between pneumococcal
isolates. Human anti-PspA responses elicited by intra-muscular
vaccination with rPspA are protective against subsequent lethal
challenge with heterologous pneumococci when passively trans-
ferred in murine models [12] and therefore the response seen in
our 6B (NW) and 23F (BAL) cohort may be of functional
significance. Both strains used in our study express PspA clade 1
similar to the PspA used for the ELISA. The absence of a NW
response in the 23F cohort could be due to low PspA expression by
the inoculated strain or adsorption of nasal antibodies to the
inoculated bacteria. The concentration of IgG to PspA in mucosal
samples is so diluted that direct functional assays or passive
transfer experiments are unlikely to succeed. Alternatively,
increased protection due to immunoglobulin responses in NW
could be tested by repeated pneumococcal challenge of subjects
with heterologous or homologous serotypes who develop exper-
imental carriage and/or enhanced immunoglobulin responses on
the first inoculation. This study is planned in our laboratory.
Murine models have demonstrated that pneumococcal coloni-
sation or vaccination results in the generation of memory CD4 T
and B cells in both the circulation and at the mucosa. The effector
CD4 T cell phenotype is mixed but includes IL-17 [14,37,58]
and/or IFNc [37,51] secreting T cells (Th-17/Th-1). NW samples
from healthy adults had very low cell counts in this study which is
not surprising given that mucosal immune cells are found in
specialised sub-mucosal lymphoid aggregates, best investigated in
humans by using surgical explants [59]. We were, however, able to
demonstrate antigen-specific T cells producing cytokine in
response to specific stimuli in BAL both before and after nasal
inoculation. Pneumococcal challenge, however, did not alter the
frequency of pneumococcal specific, cytokine secreting, CD4 T
cells in BAL. The dose of pneumococci delivered to the lung in our
non-colonised subjects is likely to have been very small and
therefore the antigenic stimulus to lung during the inoculation
period in our subjects will have been minimal. The lymphatic
drainage of the nasopharynx is to the cervical lymph nodes whilst
the lungs drain to the hilar nodes; we would therefore expect that
antigen challenge of the nasopharynx would have limited impact
on BAL lymphocytes. A recent murine model, however, has shown
that viral upper respiratory tract infections lead to the migration of
clonally-related populations of activated T cells to both upper and
lower respiratory mucosal sites [60]. These data suggests that
measuring the proportion and phenotype of antigen specific T
cells in the BAL mucosal compartment in humans may be similar
to the proportion and phenotype of effector T cell populations
present in the sub-mucosa of the nasopharynx. In this study, we
observed an increased absolute count of BAL lymphocytes and
increased percentage of CD4 memory cells in BAL at second
examination in the 23F cohort. This may reflect a response of the
respiratory tract to antigen challenge as it only occurred in the 23F
cohort and this cohort also had significant immunoglobulin anti-
pneumococcal protein responses following challenge. It is also
possible that the altered CD4 profile seen in 5/6 subjects in that
cohort resulted from the non-specific activation caused by a
previous BAL but this effect was not seen in the 6B cohort.
Alternatively, the proportion of memory CD4 T cells in the 23F
cohort (pre challenge) is lower than that in the 6B cohort (pre
challenge) and therefore the increased recruitment and proportion
of memory CD4 T cells may reflect a return to homeostatic levels
with concomitant recruitment of antibody secreting plasma cells.
There were no increases in antigen-specific CD4 T cell functional
assays to suggest specific pneumococcal activation. Current studies
in our laboratory aim to characterise the BAL lymphocyte
response to experimental human pneumococcal carriage which
will provide a more sustained antigen challenge to the lung.
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protocols in the experimental inoculations of two consecutive
cohorts of volunteers. The results in each cohort were similar in
that capsular responses were not detected in any compartment and
enhanced immunoglobulin responses were not observed in blood.
The study design was modified between 23F and 6B cohorts in an
attempt to obtain colonisation and is different from that published
previously by McCool and Weiser [25] likely influencing the
results observed. In our study whole cell ELISA data showed
significant changes only in the 23F cohort and changes in anti-
PspA response were only seen in the 23F cohort when comparing
before and after inoculation. This is most likely due to the double
dose challenge procedure employed in the 23F cohort compared
to the 6B cohort. Two doses are employed to first prime the
immune system to vaccine and then second to boost specific
responses. This has been performed successfully using rPspA (with
alum as adjuvant) in humans leading to 100 fold increases of serum
anti-PspA IgG in volunteers immunized with 125 mg of rPspA
[12]. The rPspA given in this study, however, was intra-muscular
and a larger dose. Mucosal sites were not examined for cellular or
humoral responses. Differences between the 23F and 6B cohort
described here in NW, BAL and serum cannot be ascribed to
other confounding variables such as the after effects of BAL
collection since this was obtained from both groups and non-
specific activation would have to be maintained for at least 10
weeks before being detected in post samples. BAL collection before
nasal exposure is a limitation of this study and is an important
difference between our 23F challenge model and the model
described by McCool and Weiser [25]. BAL collection may cause
systemic [61] and local [62] side effects but these are usually short
term (1–2 days) rather than long term (weeks) effects. We
attempted to minimise the pro-inflammatory effect of BAL
collection by maintaining a 2 week gap between sample collection
and challenge. We cannot rule out the possibility that BAL
collection approximately 2 weeks before challenge may have
impaired our ability to obtain colonisation following challenge
with 23F and 6B compared to the success rate of McCool and
Weiser [25].
The different results obtained from our 23F and 6B cohorts may
also be due to different antigenicity of the PspA found in the two
inoculated strains; although both strains used for inoculation
express similar PspA as that used for ELISA (all clade 1). We are
now manufacturing the PspA from each strain in order to improve
detection sensitivity but the implication of this pattern of findings is
that immunogenicity varies between natural exposures indepen-
dent of capsular type. In addition, the concentration of specific
antibody required for mucosal protection may differ between
natural and experimental exposure.
These data suggest that a mean dose of S. pneumoniae of
approximately 8,791 cfu/naris (1
st dose), and 13,830 cfu/naris
(second dose) of 23F or 44,576 cfu/naris of type 6B is sufficient to
activate mucosal defence causing a sustained increase in pneumo-
coccal specific IgG and IgA antibody to be detected in mucosal
washes 6 weeks after challenge. Pneumococcal colonisation or
higher doses of an attenuated strain may be required to elicit T cell
and immunoglobulin mediated systemic immunity.
Supporting Information
Figure S1 Capsular polysaccharide IgG responses to
23F or 6B pneumococci following 23F or 6B challenge,
respectively. ELISAs were performed using 23F or 6B capsule
as targets to measure specific IgG levels in serum (A), NW (B) and
BAL (C). Values shown are the mean antibody concentration of
triplicates in mg/ml or ng/ml as shown, pre and post 23F (n=7)or
6B (n=8) challenge (x-axis).
(TIF)
Figure S2 Nasal wash total cell counts following 23F
challenge. NW total cell counts from subjects (n=8) who were
challenged with 23F pneumococcus (A, first dose and B, second
dose). NW were collected before challenge (Pre) and on days 2 (A2
and B2), 4 (A4 and B4) and 7 (A7 and B7) post challenge (x-axis). y
axis=cell count/ml on a log10 scale (bar indicates Geometric
Mean). Samples with no cells were given a value of 0.1.
(TIF)
Figure S3 Correlation between BAL anti-pneumococcal
IgG levels and anti-PspA IgG concentration with total
lymphocyte cell count. Pre- and post-challenge data was
pooled for correlation analyses between total lymphocyte count
and anti-pneumococcal (PNC) IgG titer (A and B) or Anti-PspA
IgG concentration (C and D). A significant positive correlation was
observed for the 23F cohort (A and C) but not for the 6B cohort (B
and D). Statistical significance was determined using a Pearson
correlation test. Pearson r values and P values are indicated for
each graph.
(TIF)
Table S1 BAL differential counts (mean ± SD).
(DOC)
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